Author

P. Dreger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. Kolb· 3 shared J. Lu· 3 shared P.-M. Bruch· 3 shared S. A. Herbst· 3 shared T. Roider· 3 shared T. Zenz· 3 shared C. Mueller-Tidow· 2 shared K. Kriegsmann· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Kolb

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

S. A. Herbst, M. Vesterlund, A. J. Helmboldt, R. Jafari, I. Siavelis, M. Stahl, E. Schitter, N. Liebers, B. Brinkmann, F. Czernilofsky, T. Roider, P.-M. Bruch, M. Iskar, A. Kittai, Y. Huang, , Hu

The paper performs a proteogenomic analysis of chronic lymphocytic leukemia, identifies a new poor-prognosis subgroup (ASB-CLL) through proteomic profiling, and links it to clinical outcomes.

bioRxiv · Mar 1, 2022Cancer Biology

Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies

S. A. Herbst, V. Kim, T. Roider, E. C. Schitter, P.-M. Bruch, N. Liebers, C. Kolb, M. Knoll, J. Lu, P. Dreger, C. Mueller-Tidow, T. Zenz, W. Huber, S. Dietrich

This study compares monoculture and stromal coculture for drug screening in hematological malignancies, finding that coculture reduces drug efficacy for many compounds but increases it for JAK inhibitors.

bioRxiv · Feb 18, 2022Cancer Biology

Combinatorial drug-microenvironment interaction mapping reveals cell-extrinsic drug resistance mechanisms and clinically relevant patient subgroups in CLL

P.-M. Bruch, H. A. R. Giles, C. Kolb, S. A. Herbst, T. Becirovic, T. Roider, J. Lu, S. Scheinost, L. Wagner, J. Huellein, I. Berest, M. Kriegsmann, K. Kriegsmann, C. Zgorzelski, P. Dreger, , S. Dietrich

This paper maps drug-microenvironment interactions in CLL to identify resistance mechanisms and patient subgroups, revealing how microenvironmental stimuli and genetic alterations influence drug response.

bioRxiv · Jul 23, 2021 · PreprintCancer Biology